the efficacy data do not clearly show that PTH should be selected over antiresorptive therapies for the treatment of osteoporosis. In addition, PTH is expensive and must be administered daily via ...
Researchers at Hospital for Special Surgery (HSS) have pinpointed a cellular target that could enhance the way osteoporosis ...
investigated the effect of endogenous PTHrP on the therapeutic efficacy of PTH 1–34, to explore the molecular mechanisms that mediate the anabolic ... PTH in the treatment of osteoporosis ...
Hosted on MSN4mon
Osteoporosis market to reach $17.9b by 2033One growth driver is the increasing adoption of expensive anabolic therapies. The osteoporosis market is forecasted to grow from $10.5b in 2023 to $17.9b by 2033 at a compound annual growth rate ...
The authors next compared LP533401 to parathyroid hormone (PTH), which is the only current treatment capable ... to become a new class of anabolic drugs for osteoporosis.
NaQuinate is under clinical development by Haoma Medica and currently in Phase I for Osteoporosis. According to GlobalData, Phase I drugs for Osteoporosis have a 65% phase transition success rate ...
2008;4(9):514-523. Whether patients with high bone-turnover rates will derive most benefit from treatments that reduce bone resorption and turnover (and vice versa for patients with low bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback